10 year longitudinal change in clinical and biological characteristics of sporadic Parkinson Disease PPMI cohort
Objective: To present data on 10 year longitudinal clinical and biological characteristics of sporadic Parkinson Disease (sPD) participants in the Parkinson’s Progression Markers Initiative (PPMI)…Modulation of a subthalamic nucleus related network associated with motor response following Deep Brain Stimulation
Objective: To identify a network associated with the therapeutic effects of STN DBS Background: The network topography associated with the therapeutic effects of STN DBS…Telemedicine challenges in the management of patients with Parkinson’s disease in Central Asia.
Objective: The aim of the study is to identify challenges for telemedicine in treatment among patients with parkinsonism in Kyrgyzstan and Kazakhstan. Background: The covid-19…The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease
Objective: We aimed to evaluate the association of selected polymorphisms of COMT, DRD2, ANKK1, and DAT genes and the occurrence of levodopa-induced motor complications in…Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in achieving adequate control of motor complications in patients with advanced Parkinson’s Disease (APD). Background:…Subthalamic stimulation reshapes the reliable inherent brain state in Parkinson’s disease
Objective: To elucidate the reliable inherent state of resting-state global brain network and explore the state modulation mechanism of subthalamic stimulation (STN-DBS) on Parkinson’s disease…Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial
Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing
Objective: Report on the non-clinical in vivo pharmacokinetic and pharmacodynamic biomarker response to PROteolysis TArgeting Chimera (PROTAC®) molecules designed to induce degradation of leucine rich…Microbiota and Gastrointestinal Manifestations of Parkinson’s Disease with Arabic Translation of Gastrointestinal Dysfunction Scale
Objective: To investigate the frequency of occurrence of gastrointestinal tract GIT symptoms and their relation to patients’ clinical characteristics in addition the characteristics of gut…An European-Canadian multinational evaluation of access to care in Parkinson disease: a patient perspective
Objective: To provide a multi-national perspective of people with Parkinson disease (PwPD) on access to healthcare and the impact of the COVID-19 pandemic on those…
- « Previous Page
- 1
- …
- 121
- 122
- 123
- 124
- 125
- …
- 338
- Next Page »